Ticker Details
Myriad Genetics, Inc. Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.
IPO Date:	October 6, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$306.08M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.53 | 2.13%
Avg Daily Range (30 D):	$0.20 | 4.52%
Avg Daily Range (90 D):	$0.17 | 3.86%

Institutional Daily Volume
Avg Daily Volume:	.86M
Avg Daily Volume (30 D):	1.79M
Avg Daily Volume (90 D):	1.46M

Trade Size
Avg Trade Size (Sh.):	120
Avg Trade Size (Sh.) (30 D):	117
Avg Trade Size (Sh.) (90 D):	106

Institutional Trades
Total Institutional Trades:	11,954
Avg Institutional Trade:	$1.85M
Avg Institutional Trade (30 D):	$.98M
Avg Institutional Trade (90 D):	$1.29M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.45M
Avg Closing Trade (30 D):	$.93M
Avg Closing Trade (90 D):	$1.28M
Avg Closing Volume:	118.12K

News

Aug 7, 2026 @ 6:54 PM MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire,... Source: Bragar Eagel & Squire, P.C.

Aug 6, 2026 @ 12:00 AM MYRIAD GENETICS, INC. INVESTOR ALERT: Kirby McIner... Source: Kirby Mcinerney Llp

Jun 19, 2026 @ 9:39 AM Ovarian Cancer Diagnostics Market Size to Reach US... Source: Sns Insider

May 15, 2026 @ 3:00 PM Actress Jackie Tohn Got Results Nobody Wants But T... Source: Not Specified

May 14, 2026 @ 5:00 PM Global Cervical Cancer Diagnostics Market to Exhib... Source: Delveinsight

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-1.18	$-.46	$-.36
Diluted EPS	$-1.18	$-.46	$-.36
Revenue	$806.6M	$190.7M	$200.4M
Gross Profit	$555.2M	$127M	$137.6M
Net Income / Loss	$-112.6M	$-43.2M	$-34.1M
Operating Income / Loss	$-98.6M	$-38.9M	$-30.7M
Cost of Revenue	$251.4M	$63.7M	$62.8M
Net Cash Flow	$33.1M	$-9.2M	$-25.3M
PE Ratio

Splits
Mar 26, 2009	2:1
Sep 12, 2000	2:1